Hypoglossal Nerve Stimulation Therapy in Patients With Obstructive Sleep Apnea: Belgian Registry
Hypoglossal Nerve Stimulation (HNS) Therapy in Patients With Obstructive Sleep Apnea (OSA): Belgian Registry
University Hospital, Antwerp
225 participants
Apr 18, 2024
OBSERVATIONAL
Conditions
Summary
Hypoglossal nerve stimulation (HNS) therapy (Inspire system) is intended for the treatment of patients with moderate to severe obstructive sleep apnea (OSA) who cannot be effectively treated with the first-line treatment options. Recently, the request for reimbursement of the Inspire system in Belgium was approved. The aim is to create a multi-center registry of OSA patients that are treated with HNS (Inspire system) within routine clinical care in Belgium.
Eligibility
Inclusion Criteria5
- Any patient implanted with or receiving the Inspire HNS system and who is able to give informed consent is eligible to participate in the registry. A patient is eligible for HNS implantation if he/she meets the following criteria:
- At least 18 years old at the time of implantation
- The patient suffers from moderate to severe OSA (15 events/h ≤ AHI ≤ 65 events/h)
- The patient has failed, not tolerated or has a contraindication for continuous positive airway pressure (CPAP) and/or mandibular advancement device (MAD) therapy
- Absence of complete concentric collapse of the level of the soft palate during Drug-Induced Sleep Endoscopy (DISE)
Exclusion Criteria6
- Body mass index (BMI) \>32 kg/m².
- Combined mixed and central AHI is more than 25% of the total AHI
- Patients with complete concentric collapse at the level of the soft palate or any other anatomical deviation that could impede the proper functioning of HNS
- Patients with severely impaired neurological control over the upper airway
- Pregnancy
- Surgery performed on the soft palate in the past three months before implantation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hypoglossal nerve stimulation therapy
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06332404